Aptinyx is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The company's product candidates comprised of: NYX 2925, which is a small molecule N-methyl-D-aspartate receptors (NMDAr) modulator being developed for the treatment of chronic pain; NYX-783, which is a small-molecule NMDAr modulator in development for the treatment of post-traumatic stress disorder; NYX-458, which is a small-molecule NMDAr modulator in development for the treatment of Parkinson's disease cognitive impairment; and AGN-241751, which is for the treatment of depressive disorder.
- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States